Your browser doesn't support javascript.
loading
Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.
Gozdzik, Maciej; Pluciennik, Agnieszka; Zawiasa-Bryszewska, Anna; Nowicka, Maja; Nowicka, Zuzanna; Wagrowska-Danilewicz, Malgorzata; Kurnatowska, Ilona.
Afiliação
  • Gozdzik M; Department of Clinical Pharmacology, 1st Chair of Internal Medicine, Medical University of Lódz, ul. Kopcinskiego 22, 90-153, Lodz, Poland.
  • Pluciennik A; Department of Nephrology, Norbert Barlicki Memorial Teaching Hospital, Lodz, Poland.
  • Zawiasa-Bryszewska A; Department of Nephrology, Norbert Barlicki Memorial Teaching Hospital, Lodz, Poland.
  • Nowicka M; Department of Clinical Pharmacology, 1st Chair of Internal Medicine, Medical University of Lódz, ul. Kopcinskiego 22, 90-153, Lodz, Poland.
  • Nowicka Z; Department of Nephrology, Norbert Barlicki Memorial Teaching Hospital, Lodz, Poland.
  • Wagrowska-Danilewicz M; Department of Clinical Pharmacology, 1st Chair of Internal Medicine, Medical University of Lódz, ul. Kopcinskiego 22, 90-153, Lodz, Poland.
  • Kurnatowska I; Department of Clinical Pharmacology, 1st Chair of Internal Medicine, Medical University of Lódz, ul. Kopcinskiego 22, 90-153, Lodz, Poland.
Drug Saf Case Rep ; 6(1): 9, 2019 Oct 05.
Article em En | MEDLINE | ID: mdl-31587119
ABSTRACT
Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in non-diabetic adult patients; 75% of adult patients with MN suffer from primary idiopathic membranous nephropathy (IMN). The treatment of choice is immunosuppressive therapy, with a combination of steroids and cyclophosphamide (CYF) or chlorambucil or, as second-line treatment, calcineurin inhibitors (CNIs). One of the main concerns associated with the usage of CNIs is their potential to induce nephrotoxicity. We report a case of acute kidney injury that developed on two separate occasions within days of the administration of CNIs in a 57-year-old male patient treated for MN. The patient was qualified for first-line treatment with prednisone and CYF. Due to insufficient response and bad tolerance of CYF infusions, the immunosuppressive regimen was modified and CNIs were introduced, starting with cyclosporine A (CsA). On the third day of treatment, a severe decrease in diuresis and kidney function occurred and CsA was discontinued, resulting in a return to baseline kidney function. After 2 months, the situation repeated after attempting to introduce tacrolimus.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article